Log in

NASDAQ:NTGNNeon Therapeutics Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$3.07
0.00 (0.00 %)
(As of 05/6/2020)
Add
Compare
Today's Range
$3.07
Now: $3.07
$3.07
50-Day Range
$2.77
MA: $3.03
$3.07
52-Week Range
$0.88
Now: $3.07
$6.25
VolumeN/A
Average Volume516,108 shs
Market Capitalization$88.93 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.81
Neon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Read More
Neon Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.1Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.67 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NTGN
CUSIPN/A
CIKN/A
Phone617-337-4701

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.50 per share

Profitability

Net Income$-79,780,000.00

Miscellaneous

Employees102
Market Cap$88.93 million
Next Earnings DateN/A
OptionableNot Optionable

Receive NTGN News and Ratings via Email

Sign-up to receive the latest news and ratings for NTGN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Neon Therapeutics (NASDAQ:NTGN) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Neon Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neon Therapeutics in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Neon Therapeutics
.

How were Neon Therapeutics' earnings last quarter?

Neon Therapeutics Inc (NASDAQ:NTGN) issued its quarterly earnings results on Monday, March, 2nd. The company reported ($0.63) EPS for the quarter, beating analysts' consensus estimates of ($0.66) by $0.03.
View Neon Therapeutics' earnings history
.

What price target have analysts set for NTGN?

5 equities research analysts have issued 1 year target prices for Neon Therapeutics' shares. Their forecasts range from $2.18 to $12.00. On average, they anticipate Neon Therapeutics' share price to reach $7.06 in the next year. This suggests a possible upside of 130.0% from the stock's current price.
View analysts' price targets for Neon Therapeutics
.

Has Neon Therapeutics been receiving favorable news coverage?

News stories about NTGN stock have trended somewhat negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Neon Therapeutics earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the stock's share price in the next few days.
View the latest news about Neon Therapeutics
.

Who are some of Neon Therapeutics' key competitors?

What other stocks do shareholders of Neon Therapeutics own?

Who are Neon Therapeutics' key executives?

Neon Therapeutics' management team includes the following people:
  • Mr. Hugh O'Dowd, Pres, CEO & Director (Age 54)
  • Dr. Eric S. Lander, Founder & Director (Age 62)
  • Dr. Yasir B. Al-Wakeel, Chief Financial Officer (Age 37)
  • Dr. Richard Gaynor, Pres of R&D (Age 69)
  • Dr. Edward Fritsch Ph.D., Founder and Chief Technology Officer

When did Neon Therapeutics IPO?

(NTGN) raised $101 million in an IPO on Wednesday, June 27th 2018. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley, BofA Merrill Lynch and Mizuho Securities served as the underwriters for the IPO and Oppenheimer was co-manager.

What is Neon Therapeutics' stock symbol?

Neon Therapeutics trades on the NASDAQ under the ticker symbol "NTGN."

What is Neon Therapeutics' stock price today?

One share of NTGN stock can currently be purchased for approximately $3.07.

How big of a company is Neon Therapeutics?

Neon Therapeutics has a market capitalization of $88.93 million. The company earns $-79,780,000.00 in net income (profit) each year or ($2.86) on an earnings per share basis. Neon Therapeutics employs 102 workers across the globe.

What is Neon Therapeutics' official website?

The official website for Neon Therapeutics is www.neontherapeutics.com.

How can I contact Neon Therapeutics?

Neon Therapeutics' mailing address is 40 ERIE STREET SUITE 110, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-337-4701 or via email at [email protected]

This page was last updated on 8/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.